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Abstract
Background: Modulation of cellular signaling pathways can change the replication/differentiation balance in cancer stem
cells (CSCs), thus affecting tumor growth and recurrence. Analysis of a simple, experimentally verified, mathematical model
suggests that this balance is maintained by quorum sensing (QS).
Methodology/Principal Findings: To explore the mechanism by which putative QS cellular signals in mammary stem cells
(SCs) may regulate SC fate decisions, we developed a multi-scale mathematical model, integrating extra-cellular and intra-
cellular signal transduction within the mammary tissue dynamics. Preliminary model analysis of the single cell dynamics
indicated that Dickkopf1 (Dkk1), a protein known to negatively regulate the Wnt pathway, can serve as anti-proliferation
and pro-maturation signal to the cell. Simulations of the multi-scale tissue model suggested that Dkk1 may be a QS factor,
regulating SC density on the level of the whole tissue: relatively low levels of exogenously applied Dkk1 have little effect on
SC numbers, whereas high levels drive SCs into differentiation. To verify these model predictions, we treated the MCF-7 cell
line and primary breast cancer (BC) cells from 3 patient samples with different concentrations and dosing regimens of Dkk1,
and evaluated subsequent formation of mammospheres (MS) and the mammary SC marker CD44
+CD24
lo. As predicted by
the model, low concentrations of Dkk1 had no effect on primary BC cells, or even increased MS formation among MCF-7
cells, whereas high Dkk1 concentrations decreased MS formation among both primary BC cells and MCF-7 cells.
Conclusions/Significance: Our study suggests that Dkk1 treatment may be more robust than other methods for eliminating
CSCs, as it challenges a general cellular homeostasis mechanism, namely, fate decision by QS. The study also suggests that
low dose Dkk1 administration may be counterproductive; we showed experimentally that in some cases it can stimulate
CSC proliferation, although this needs validating in vivo.
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Introduction
There is growing evidence that cancer arises from self–renewing
malignant SCs – known also as ‘‘cancer initiating cells’’ or ‘‘stem-
like cells’’ – that are resistant to standard therapy [1]. Such cells
have been amply documented in BC and are considered to be a
reason for the failure of therapy and a source of relapse [2,3].
Understanding the key molecular mechanism governing the
transition of BC-SCs from self-renewal to differentiation could
indicate how to manipulate fate decision in these cells, so as to
drive most or all of the proliferating cells into differentiation. The
resulting differentiated cells would have a significantly reduced
replication capacity and would be more sensitive to standard
therapy and thus easier to eliminate [4].
BC-SCs’ self-renewal is mediated by different signaling
pathways, mainly by Wnt [5,6], Notch [7], and E-cadherin [8]
(see detailed description in the Materials and Methods and reviews
in Refs. [9], [10], and [11]). These signaling pathways are
complex, involving an intricate interplay of negative and positive
stimuli, which has complicated researchers’ attempts to compre-
hend the system as a whole. Traditional experimental biology
paradigms do not suffice here, thus calling for new methodologies
for disentangling SC control mechanisms.
Previously, we constructed and analyzed a general mathemat-
ical model for developing tissues. Based on model analysis we
asserted that the balance between replication and differentiation is
mainly controlled by a negative feedback on SC proliferation
(denoted QS; [12,13]). This mathematical result was supported by
laboratory experiments showing that, as the QS theory suggests
and independently of the initial SC fraction, there is a fixed
proportion of SCs (marked by either CD44 or CD44+/24lo/
ESA+) at population confluence [14].
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relatively simple mathematical model for the major intra-cellular
processes regulating fate decision in mammary SCs, and
implementing it within the general developing tissue model. Using
this approach we explored the interactions between events
occurring on the intra-cellular scale and events occurring on the
tissue scale, and examined how the cellular pathways might serve
as a control system that integrates signals from the environment to
regulate cell fate. Preliminary analysis of the cell model has singled
out Dkk1 as a plausible mechanism, whose modulation can divert
a BC-SC from proliferation into differentiation [12]. However, it
was not a priori evident that the same mechanism would be
effective when the dynamics at the tissue scale was to be examined,
since multiple, non synchronous feedbacks could drive the larger
system to an unexpected outcome. Therefore, we simulated the
combined multi-scale mathematical model to study the role of
Dkk1 in BC-SC regulation, in order to predict the conditions,
within the tumor environment, which divert BC-SCs from
proliferation.
Our mathematical model, fully presented in this work (below
and in Text, S1), provides a general theory for the role of Dkk1 in
SC regulation, and predicts that Dkk1 in the inter-cellular space
can balance proliferation and differentiation of SCs through its
effect on the Wnt and, indirectly, on the Notch pathways. Our
model further predicts that the addition of small doses of
exogenous Dkk1 will not decrease, and may even slightly increase,
mammary cell proliferation, whereas large doses of Dkk1 will
divert proliferating SCs to differentiation. We present herein
experimental results in MCF-7 cells and in BC cells from a
patient’s biopsy, which support the predictions of the mathemat-
ical model.
Results
Mathematical model
Our model is a multi-scale tumor model, aimed at exploring the
interactions between events occurring on the molecular scale and
events occurring on the tissue scale, and at examining how the
cellular pathways can serve as a system that integrates signals from
the environment to regulate cell fate.
Modelling the tissue dynamics
In order to model the structure of the tissue, containing both
continuous protein activities and discrete cellular developmental
and spatial states, we used a hybrid cellular automata (HCA)
formalism,[15] and added to it a random choice of the daughter
cell settling sites [13,16]. Our tissue model is a 2-dimensional HCA
grid of 800 cells. Each SC on the grid has the form of our SC
model described below.
The full description of our cellular automata model can be
found in [12,13,16] In brief, our tissue model assumes that SCs,
whose cell cycle duration is t, can divide symmetrically, creating
new SCs, and alternatively, can differentiate. The third possibility,
namely, division of a SC to two differentiated cells is ignored for
simplicity of the model. SC decision is determined by the SC’s
intra-cellular protein levels that are influenced by micro-
environmental interactions, as detailed below. When no vacant
neighboring sites are available for replicating into, a SC will
remain quiescent. The differentiated cell compartment includes all
differentiated descendants of a SC, whose life span, W, is limited
and whose brief proliferation is ignored here, for simplicity. A cell
that dies creates an empty grid site, which can become occupied
by a proliferating adjacent cell.
Modelling signal transduction
We formulated the mathematical model of mammary SCs fate
decision, based on literature information (see ‘‘Biological back-
ground for the mathematical model’’ in SI), suggesting that Wnt
signaling activates LEF/TCF protein complex leading to up-
regulation of proliferation factors (PF), Dkk1 and proteins involved
in the Notch signaling pathway. The Wnt pathway can down-
regulate E-cadherins, whereas Dkk1 and E-cadherins can inhibit
Wnt signaling. Activation of Notch receptor by a transmembrane
ligand DSL, presented by an adjacent cell, causes up-regulation of
Hes, which inhibits the differentiation factors (DF). Notch activity
can be further stimulated by LEF/TCF (See Fig. 1 for graphical
representation).
The intracellular model is formulated as a set of coupled
ordinary differential equations, describing the dynamics of the
proteins comprising the modeled regulatory pathways. The main
model equations and their short explanation are given below.
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In all the equations, f :
  denote increasing functions; f ;
  -
decreasing functions. In Eq. 1, St ðÞdenotes signal intensity of the
Wnt pathway in a cell at time t; Wt and Dt are total levels of Wnt
and Dkk1 proteins, respectively, in the close environment of the
cell; f
:
F – Wnt signal intensity as a function of Wt; f
;
S – inhibition
of the Wnt signal by Dkk1, as a function of Dt. In Eq. 2, D denotes
the level of Dkk1 produced by the cell; f
:
D – dependence of Dkk1
synthesis rate on activated LEF/TCF; mD – Dkk1 degradation
rate. In Eq. 3, L denotes the level of activated LEF/TCF; Eb–E -
cadherin bound to neighboring cells; f
;
L – dependence of LEF/
TCF activation rate on the bound E-cadherin; mL - LEF/TCF
degradation rate. In Eq. 4.1, E denotes the total E-cadherin
level; f
;
E – dependence of E-cadherin synthesis rate on S;
mE – E-cadherin degradation rate. In Eq. 4.2, Eb,i denotes the
level of the E-cadherin bound to the neighbouring cell into i-th
direction; Ei – level of E-cadherin in the neighbouring cell situated
in i-th direction from the considered cell; kb – E-cadherin binding
coefficient. In Eq. 4.3, the total level of bound E-cadherins in the
cell is computed as a sum of E-cadherins bound to all the six
neighbouring cells. In Eq. 5, P denotes the level of PF; f
:
P –
dependence of PF synthesis rate on L; mP – PF degradation rate.
In Eq. 6.1, N denotes Notch receptor level; pN– Notch receptor
synthesis rate; f
;
N – dependence of Notch receptor degradation
rate on L. In Eq. 6.2 the level of activated Notch receptors, Nr,i s
computed as a minimum between the total Notch receptor level
and the level of DSL receptors available from all the adjacent cells,
denoted by Nl,i for the adjacent cell in i-th direction. In Eq. 7, H
denotes HES level; f
:
H– dependence of HES synthesis rate on Nr;
mH – HES degradation rate. In Eq. 8, Mdenotes level of DF; f
;
M –
dependence of DF synthesis rate on Nr; mM – DF degradation
rate. For the complete mathematical model and the detailed
explanation of every equation, see SI.
It is important to bear in mind that the effect of Notch and Wnt
on the proliferation/differentiation balance is taken account of by
the balance between the amount of PF and DF regulated by the
former and latter biochemical pathways, respectively. The
synthesis of PF is up-regulated by the activated LEF/TCF
transcription factors. Degradation of PF and DF is proportional
to their level (first order degradation). The cell replicates upon PF
accumulation above a certain threshold, cp and the availability of
an adjacent empty site. The switch to differentiation is induced
when DFs reach a certain threshold cM. Note that in our model,
SCs transit to quiescence when the levels of the proliferating
factors are below the threshold cP, but differentiating factor levels
have not reached cM.
Figure 1. Schematic representation of the mathematical model of fate decision by breast cancer stem cells. Wnt signaling pathway
induces LEF/TCF activation, resulting in up-regulation of Pf, Dkk1 and Notch signaling activators. Wnt signaling pathway also down-regulates E-
cadherins. Dkk1 and E-cadherins inhibit Wnt signaling pathway. Activation of Notch signaling pathway by DSL up-regulates Hes expression, which
inhibits Df. Pf, proliferation factor; Df, Differentiation factors; CP, Pf threshold; CM, Df threshold; DSL, Delta, Serrate, Lag-2; Dkk1, Dickkopf1 protein.
Pale blue – Wnt protein; purple – Notch pathway protein; green arrow – activation; grey arrow – inhibition; dashed arrow – threshold-dependent
effect.
doi:10.1371/journal.pone.0024225.g001
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proliferation
Our primary interest in this paper was to examine SC response
to changes in the local environment, such as increase or decrease
in the number of neighbors within the tissue, or addition of
regulatory molecules to the environment. In terms of our
suggested model, such events will produce feedbacks, which are
realized in some of the signals received by the SC. These signals
include the level of external Dkk1 and the level of external Wnt
entering the cell, the number of DSL receptors on the surface of
neighboring cells, as well as the number of E-cadherins on
neighboring cells, which determines the proportion of bound E-
cadherins. Our preliminary analysis of a single SC behavior
suggests that an increase in the concentration of either Dkk1 or E-
cadherin decelerates proliferation as well as accelerating differen-
tiation. From [12], it also follows that reducing Wnt or DSL could
yield a similar outcome. For practical reasons, here we focused
attention on the addition of Dkk1, as the number of receptors on
the cell surface cannot be externally controlled and the other
ligands are also less controllable. However, other anti-Wnt
pathway treatments are currently investigated (Kogan et al., in
preparation).
We simulated the effects of Dkk1 on cell proliferation in the
normal mammary tissue. The results indicate that the number of
SCs in culture is independent, to any significant extent, of the
concentrations of Dkk1 that are lower than 13 ng/ml. Above this
concentration, the number of SCs, both proliferating and
quiescent, rapidly decreased, due to differentiation (grey full
circles in Fig. 2). That in our simulations SCs are eliminated only
by transition to differentiation, is self-evident from the structure of
the model, not allowing for SC apoptosis.
Our simulations further suggest that the dose effect of Dkk1 on
SC proliferation depends on the particular signaling defects.
Association of defective Wnt and Notch signaling with BC points
to their possible role in carcinogenesis [17]. We simulated Dkk1–
dependent proliferation in BC-SCs characterized by aberrant
activity in the signal transduction pathways. For that, we ‘‘tittered
in’’ the effects of the respective molecular defects in the modeled
signaling pathways, on Wnt/Noch activation or on E-cadherin
loss, and observed the effects. Mutations in Notch and Wnt
signaling pathways were simulated by 5 to 20 percent increase in
the rate of Notch receptor synthesis and the Wnt ligand expression
level, respectively. Mutations in E-cadherin were simulated by 5 to
20 percent increase in E-cadherin concentration, required for
inhibition of LEF/TCF activity (see explanation in the Materials
and Methods section). Our simulation results show that increasing
the level of these molecules, which represent mutation-driven
activation of signaling pathways, did not change the qualitative
dependence on Dkk1, but did increase the number of BC-SCs in
culture (Fig 2). As in normal cells, here too the effect of Dkk1 was
biphasic. Below a threshold of Dkk1 concentration, there was no
significant Dkk1 effect. Above that threshold concentration, which
was somewhat higher than for normal cells, BC-SC number
decreased in a Dkk1 dose dependent manner (Fig. 2). It can be
seen in Fig. 2 that this threshold Dkk1 concentration increases
with the expression level of the signaling proteins induced by the
particular mutations. In addition, under relatively low Dkk1 levels,
the rate of SC proliferation increased with increasing aberration in
the rate of Notch receptor synthesis.
Taken together, our model simulations show that, whereas
addition of small amounts of Dkk1 do not change or sometimes
even increase SC numbers, there exists a threshold of exogenous
Dkk1 concentration, above which SC numbers are reduced,
through SC differentiation in a dose-dependent and a mutation-
dependent manner, until all SCs undergo differentiation.
Experimental testing of model predictions
The mathematical model simulations suggested that increasing
Notch receptor activity will increase BC-SCs numbers (Fig. 2C).
We used the long established ER+ breast cancer cell line MCF-7
and measured the effect of recombinant human Notch-receptor
ligand DLL4 (rhDLL4) on the proportion of BC cells character-
ized by stem-cell phenotype CD44+CD24-/low[1,7], and on MS
formation, as a measure of SC number; [7,18] MS are colonies
formed in suspension from single cells and therefore measure
clonogenic potential; cf. ref. [7]). We found that increasing the
Notch receptor activity by addition of rhDLL4 increased the
Figure 2. Simulations of Dkk1 effects on number of SCs in
normal and mutated mammary tissue. Continuous administration
of Dkk1, 0 to 25 ng/mL, for 48 h to normal or mutated mammary tissue
was simulated. The model was simulated over three months after Dkk1
treatment. The average number of SCs, over the last three simulated
days, was calculated over 50 simulation experiments for each
combination of concentration and cell type. A. Cells bearing mutations
in the amount of E-cadherins required for inhibiting LEF/TCF activation,
vs. normal cells. B. Cells bearing mutations increasing Wnt ligand
expression vs. normal cells. C. Cells bearing mutations increasing Notch
receptor synthesis vs. normal cells.
doi:10.1371/journal.pone.0024225.g002
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low cells (Table 1; P,0.05). In keeping with this positive effect of
Notch activity on BC-SCs number, we tested the effect of DAPT, a
c-secretase inhibitor that blocks Notch receptor activity. DAPT
reduced both MS formation and the percentage of CD44+CD24-/
low cells (Table 2; P,0.05). High activity of Notch4 in BC-SCs
was recently detected in CD44+CD24low cells by the presence of
relatively high levels of the cleaved Notch4 intra-cellular domain
[19]. To confirm the role of Notch activation in BC-SCs, we
knocked down Notch4 expression by siRNA. Following treatment
with all siRNA sequences, the CD44+CD24-/low population
(Fig. 3A) and number of MSs formed (Fig. 3B) were significantly
reduced.
When the mathematical model was used to simulate Wnt
signaling effects on BC-SCs, it predicted that low Dkk1
concentrations should not affect, or somewhat increase SC
proliferation, whereas above a threshold of Dkk1 concentration
the BC-SC number would decrease, depending on the dose of the
exogenously applied Dkk1 (Fig 2). To test this prediction, we
treated MCF-7 breast cancer cells by graded doses of Dkk1
applied at schedules detailed in Materials and Methods. Under all
conditions, Dkk1 stimulated MS formation at the concentration of
1.0 ng/mL while a Dkk1 concentration equal to or larger than 5.0
ng/mL consistently reduced MS formation (Fig. 4). For example, a
single exposure to 1 ng/mL Dkk1 stimulated MS formation by
1.5–fold compared to untreated, while single exposure to 100 ng/
mL Dkk1 reduced MS formation to 30 percent of controls
(Fig. 4A). We observed this dose–response pattern under all
regimens of Dkk1 introduction to cells, suggesting that multiple
applications were redundant (Figs 4E–F). Whereas the biphasic
effects on MS formation are significant, Dkk1 only significantly
reduced CD44
+CD24
-/low expression in MCF-7 cells at high
concentrations (100 ng/mL; p,0.02, Fig. 5), whereas the
increased expression at lower concentrations is more variable.
Since the ER+ MCF-7 cell line was established more than 30 years
ago, we wished to test our findings on fresh primary ER+ human
tumor samples. We therefore tested MS formation from ER+
primary BC cells from three patient samples and demonstrated
that, in contrast to the MCF-7, low Dkk1 concentrations do not
affect MS formation but higher concentrations significantly reduce
MS numbers (Fig. 6; p,0.001). This suggests that ER+ primary
breast cancer cells are dependent on the Wnt pathway for SC
activity as measured by the MS assay.
Discussion
In this study we investigated how manipulation of molecular
signaling pathways can influence BC-SC fate decision, potentially
yielding therapeutic benefit. To this end we constructed a multi-
scale mathematical model, which integrates intra-cellular and
extra-cellular signal transduction in normal and malignant
mammary tissues. Our preliminary analysis suggested that Dkk1
serves as anti-proliferative and pro-maturation signal in the
context of a single cell [12]. Yet, it was not a priori evident that
the same effect would be preserved when the dynamics of multiple
cells at the tissue scale was to be examined. This is due to the
activity of multiple, non synchronous feedbacks in the larger scale
system, which could drive it to an unexpected outcome. In
addition, in contrast to the relatively simple effect of Dkk1 on a
single isolated SC, in tissue the effect can be non-monotonic and
dose-dependent, having clear qualitative thresholds. Therefore, it
was important to test what will be the influence of exogenous Dkk1
on the fate of SCs that function within the tissue environment.
Simulations of our model point to Dkk1 as a plausible mediator
of SC fate decision, which can switch tissue BC-SCs from
replication to differentiation in a dose-dependent manner. Our
results suggest the existence of a critical Dkk1 concentration,
below which SC replication remains largely unaffected or, even,
slightly increases, and above which it is suppressed. A relatively
small change in Wnt or Notch activity, appears to alter the Dkk1
threshold values and the Dkk1 levels that are required for SC
proliferation to be reduced to zero.
These predictions were experimentally tested by checking the
effects of Dkk1 on MS formation and on the proportions of cells
bearing the BC-SC phenotype CD44
+CD24
-/low. In accordance
with model predictions, low levels of Dkk1 (less than 10 ng/ml) do
not significantly change the number of MS formed in ER+ BC
cells from three primary samples primary BC, while doses of
10ng/ml or higher significantly reduce the number of MS formed
Table 1. Effects of the Notch receptor ligand rhDLL4 on CD44
+ CD24
low expression and mammosphere formation.
rhDLL4 Exposure (Hours) Fold Change Mammosphere formation Fold Change CD44+ CD24low
24 2.2360.01* 1.5960.03*
48 2.460.22* 1.4961.11*
*p ,0.05, data collected from 3 independent experiments and represented as mean 6 SEM.
Recombinant human Delta4 (rhDLL4) in gelatin was adsorbed to tissue culture plates before plating of MCF7 cells for 24 and 48 hours. The cells were collected and
analyzed for expression of CD44
+ CD24
low and tested for mammosphere formation. At both time points the CD44
+ CD24
low expressing population and number of
mammosphere formed were significantly increased following exposure to the ligand.
doi:10.1371/journal.pone.0024225.t001
Table 2. Effects of the Notch receptor inhibitor DAPT on CD44
+ CD24
low expression and mammosphere formation.
DAPT Treatment (Hours) Fold Change Mammosphere formation Fold Change CD44
+ CD24
low
48 0.7560.19
* 0.3760.13
*
*p ,0.05, data collected from 3 independent experiments and represented as mean 6 SEM.
The gamma secretase inhibitor, DAPT, was added to culture of MCF7 cells for 48 hours. The cells were collected and analysed for expression of CD44
+ CD24
low and
tested for mammosphere formation. The CD44
+ CD24
low expressing population and number of mammosphere formed were significantly decreased following exposure
to the inhibitor.
doi:10.1371/journal.pone.0024225.t002
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by results in cells taken from primary BC cells.
Comparatively large Dkk1 concentrations reduced BC-SC
numbers down to 25 percent of controls in MCF-7 cells, whereas
MCF7 cells differed from primary tumor cells in response to low
dose Dkk1, even though these cells were of the same ER+ breast
cancer phenotype. Dosing Dkk1, 1ng/ml, significantly increased
mammosphere formation in four out of six MCF7 experiments.
Several explanations, relating to the assumed model parameter
values, may account for this phenomenon. Possibly, such strong
effect can be observed in our model under parameter values that
are different from those we estimated. However, as in our study we
wished to focus the investigation on the problem of fate decision,
we kept other parameters of the system constant throughout the
simulations and preferred not to investigate putative effects on
other elements of the system, such as the differentiated cell
mortality (but see, e.g[14]).
Higher Dkk1 doses were necessary for driving a similar pattern
of change in the percentage of CD44
+CD24
-/low, but here the
effect was more variable, probably due to lower sensitivity of this
assay, so that only the reduction of BC-SC markers under high
Dkk1 concentrations showed statistical significance. Over all, these
results imply that tissue differentiation requires high doses of Dkk1.
To directly demonstrate that Dkk1 at high concentrations induces
mammary differentiation we plan to look at normal primary
mammary cells, where markers of differentiation are well defined.
We believe that this experiment will provide more conclusive
information than our initial experiments.
Although the model predicts that high Dkk1 concentrations
completely eliminate SCs from the cell culture, we observed no
BC-SC eradication. Note, however, that according to model
predictions, the dose of Dkk1, which is required for SC
elimination, largely depends on the mutations leading to the
changes in activity of Wnt, Notch or E-cadherin; a change of 15%
in Wnt or Notch activity would almost double the Dkk1 levels
required for SC proliferation to be reduced to zero. As there is no
information about the genetic make-up of MCF7 cells and
primary cancer samples used in the experiments, our simulations
attempted to capture only the qualitative pattern of SC growth.
Moreover, the difficulty to obtain pure BC-SCs and culture them
without change of phenotype and function, render the evaluation
of cancer SCs parameters challenging, at present. This techno-
logical problem also impinges on the present ability to retrieve the
quantitative effect of Dkk1 on SC growth.
In distinction to the present system, a recently developed
mathematical model of Wnt signaling derived the parameter
values from measurements in the more accessible Xenopus oocytes
[20]. However, since the quantitative cause–effect relationships of
Dkk1 are context dependent (viz. quorum sensing), in our model
construction we were limited by experimental methods applicable
to BC–SCs.
Recent studies show that introduction of Dkk1 to lag–phase
mesenchymal SCs, stimulates proliferation [21], and that Dkk1
allows SCs from bone marrow stroma to re-enter the cell cycle by
inhibiting the Wnt/b-catenin signaling pathway [7]. In contrast to
stimulating proliferation, Dkk1 appears to induce neural differen-
tiation of embryonic SCs [22] and differentiation of colon cancer
cells [23]. Our results may resolve these contradicting views of
Dkk1 effect, as they suggest that the observed discrepancies
reported in the literature result from experiments conducted in
different regions of Dkk1 concentration–effect curves. Our model
predictions are further corroborated by recent experiments
suggesting that the expression levels of Dkk1 were down-regulated
in LM-MCF-7 cells, as compared to MCF7 cells, and that as a
result, LM-MCF-7 cells have relatively high proliferation ability,
via losing control of b-catenin/TCF transcription cascade. It has
Figure 3. Effects of Notch4 on percentage CD44
+ CD24
low cells
and mammosphere formation. siRNA designed to four unique sites
in the Notch4 receptor were used to inhibit Notch signalling. A non-
specific siRNA was used as a control for transfection. siRNA, was
trasfected to MCF7 cells in monolayer for 72 h before analysis of
CD44
+CD24
-/low cell surface markers (A), or mammosphere forming
assay (B). Data collected from three independent experiments in A or
two independent experiments in B are represented as mean 6 SEM.
Asterisks mark statistically significant differences (p#0.05 by I-test).
doi:10.1371/journal.pone.0024225.g003
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therapy to inhibit the development of BC cells [24].
Our model assumes that the Notch and the Wnt signaling
pathways are linked through the inhibition of the Notch receptor
degradation by activated LEF/TCF. This assumption is yet to be
experimentally supported for BC cells. Implementing it in our
mathematical model is justified by indirect evidence (see Materials
and Methods), and backed by our conviction that these two
pathways cannot be independent, as is customarily believed, but,
rather, that a link between the two pathways must exist, since the
transition between proliferation and differentiation should be
balanced.
Another model prediction is that increasing the rate of Notch
receptor synthesis increases SC proliferation in a dose dependent
manner (see SI for precise assumption and formulation). This is
seen in our simulations, and is explained by the model’s
assumption that cell’s fate decision is made according to the
relation between the amounts of PF and DF: the higher Notch
activity gets, the lower is the rate of increase in the amounts of DF
relative to the rate of increase in the amounts of PF. As a result, PF
within SCs will tend to reach the proliferation threshold
increasingly quicker than DF, and population proliferation rate
will increase.
To verify this model prediction we mimicked an increase in
Notch receptor activity by addition of rhDLL4. This resulted in
augmented MCF-7 cell line MS formation and an increase in the
numbers of CD44+CD24-/low cells. We tested the power of these
results by two further experiments: first, we studied the effect of
DAPT, which blocks Notch receptor activity, on BC-SC
proliferation and showed that it was significantly reduced.
Secondly, we knocked down Notch4 expression by siRNA and
showed that the CD44+CD24-/low population and number of
MSs formed were significantly reduced. Similar experimental
results have been reported by us previously [19], but here we
provide a model predicting these phenomena, an underlying
mechanism explaining them, and an experimental support for
their existence. We are aware that adding increasing concentra-
tions of the Notch ligand to mimic the dys-regulation found in
Figure 4. Dkk1 affects mammosphere formation by MCF-7 cells. MCF-7 cells were pre-incubated with graded concentrations of Dkk1 (0, 1, 5,
10, 50, 100 ng/mL) in serum free medium for 24 or 48 h, and then plated for mammosphere forming assay for seven days. For cells preincubated for
48 hours, Dkk1 was refreshed after 24 hours of preincubation. In the course of the seven–day incubation in mammosphere medium, Dkk1 was either
absent (panels A, D), introduced at pretreatment concentration once at the beginning of the assay (panels B,E) or refreshed thereafter every 24 hours
(panels C,F). P values for the overall variance of all data points were generated by Kruskall–Wallis test. Asterisks mark statistically significantly different
(p#0.05) individual comparisons of Dkk1–treated cells and Dkk1–free controls (Mann–Whitney U test).
doi:10.1371/journal.pone.0024225.g004
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the addition of exogenous ligands simulates the molecular defects
found in primary breast cancers. However, the reported results of
the DAPT and the siRNA experiments provide a support for the
model’s prediction about the relevance of Notch signaling to
proliferation of cancer cells. Collectively, these results establish
that the number of CSCs increases or decreases in accordance
with the activation or inhibition of the Notch pathway,
respectively, as predicted by the mathematical model and in
agreement with our previous studies.
Mutations and gene methylation changes leading to aberrant
Notch, Wnt and E-cadherin signaling have been found in many
cancers and particularly in BC [25,26,27]. Here we modeled the
molecular defects that increase activation of Wnt or Notch
pathways or impede E-cadherin-mediated inhibition of LEF/TCF
activity. Our simulations indicate that the more pronounced these
defects are - particularly defects in the Notch pathway - the greater
is the increase in BC-SC proliferation, and the higher is the
concentration of Dkk1 that is required for SC elimination. Our
model predicts that mutations that increase Notch activation by as
little as 5 percent allow BC-SC proliferation at Dkk1 concentra-
tions that induce differentiation of normal SCs (Fig. 2). This
implies a mechanism by which BC-SCs, the key component of
minimal residual disease, can replace the nonmalignant SCs in
their niche, e.g., bones [28,29,30].
To sum up, our mathematical model is a new multi-scale model
for describing SC fate decision in developing tissues, which
combines intracellular pathways with replication/differentiation
behavior within the cell population. The model provides a general
theory for the role of Dkk1 in SC proliferation, suggesting that
Dkk1 may be the molecular mechanism mediating SC fate
decision and that this is done by a QS mechanism. Specifically, the
model predicts that Dkk1 controls the balance between prolifer-
ation and differentiation in individual cells, rather than inhibiting
proliferation alone, and that the addition of small doses of
exogenous Dkk1 does not decrease, and sometimes even increase,
mammary cell proliferation, whereas large doses of Dkk1 will
divert proliferating SCs to differentiation. Furthermore, the model
predicts that increasing the rate of Notch synthesis increases SC
proliferation, per se, rather than just reducing differentiation. We
present herein laboratory experiments in MCF-7 cells and in ER+
BC cells biopsied from patients, which prospectively verify the
mathematical model.
Our results suggest that large Dkk1 boluses applied in situ may
serve for differentiation therapy. Such differentiation therapy has
been suggested by Sell and others [31]. Here we present the
theoretical basis for this therapy modality. Our study implies that
Dkk1 therapy may be more robust than other methods, as it
challenges a general cellular homeostasis mechanism, namely, fate
decision by QS. Inappropriate Dkk1 administration may be
counterproductive, as it may stimulate CSC proliferation. These in
vitro findings will have to be verified by limiting dilution
transplantation experiments on BC-SC activity in mouse xenograft
models. Hopefully, this work will provide an impetus for careful
examination of differentiation–directed strategies for BC therapy.
Materials and Methods
Model simulations
To describe a reasonably sized tissue we used the honeycomb
grid on closed surface (determining that each cell may have up to 6
adjacent neighbors) with 800 cells (the dimensions of the grid were
40620 cells). This architecture does not allow the edges to affect
the system’s behavior; it minimizes the effect of grid’s size and has
been found sufficient for exploring the properties of quorum
sensing. It should be noted again here that our main concern in
this work was to study what may be the mechanism of fate decision
and not to analyze the specific cellular automata structure. This is
done elsewhere (in preparation).
The tissue model grid was initially seeded by 36 randomly
placed SCs and was simulated over three months immediately
following Dkk1 treatment. The average number of SCs, over the
last three simulated days, was calculated over 50 simulation
experiments for each combination of concentration and cell type.
It should be emphasized that the model does not make any specific
Figure 5. Dkk1 affects CD44
+CD24
-/low expression in MCF-7
cells. MCF-7 cells were incubated with graded concentrations of Dkk1
(0, 1, 5, 10, 50, 100 ng/mL) in serum free medium for 48 h, Dkk1 was
refreshed after 24 hours of incubation. Percentage of CD44
+CD24
-/low
cells was then analysed by flow cytometry and fold change compared
to DKK-free control calculated. P values were generated by individual
comparisons of Dkk1–treated cells and Dkk1–free controls (Mann–
Whitney U test).
doi:10.1371/journal.pone.0024225.g005
Figure 6. Effect of Dkk1 treatment on mammosphere forma-
tion by primary human invasive breast cancer cells. Non-
adherent breast cancer cells were plated in the presence of Dkk1 (0, 1,
5, 10, 50, 100 ng/mL) and cultured for 7 days of mammosphere forming
assay. Data for each concentration of Dkk1 are expressed as the fold
change in mammosphere formation compared to untreated controls
(0 ng/mL). P values were generated by ANOVA. Asterisks mark
statistically significant differences (p#0.05 by I-test).
doi:10.1371/journal.pone.0024225.g006
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evolution is directed only by its stated underlying developmental
rules, so that the final number of SCs in the system is independent
of the specific pattern of SC position. Moreover, because the focus
of this model is on the combined intracellular/extracellular effects
on SC’s fate decision, the independent properties of the tissue
model are not explore here; for their investigation see [14] and in
preparation).
The mathematical model was numerically simulated by
calculation of per-cell expression levels of all modeled proteins
for the duration of the simulated process and calculation of the
intra-cellular dynamics for all the cells.
Calculation of model parameters
Initial parameters for normal mammary SCs were chosen such
that tissue survival to confluence is guaranteed (see Table S1,
listing all the parameter values of the model).
No experimental data were found in the literature for relating
the quantitative effects of mutations to changes in expression of the
signal transduction proteins in breast cancer cells. Yet, since our
aim was to get a qualiitative understanding of such effects, we
chose representative values for each considered mutation of the
‘‘wild type,’’ which lead to 2-4-fold increase in SC numbers, as a
rough approximation to putative oncogenic mutations. For this
reason, defects in signaling pathways were represented by an
increase of 5 to 20 percent in Notch receptor synthesis, or in Wnt
ligand expression or in E-cadherin concentration required for
inhibition of LEF/TCF activity.
To match up the model–specific units of Dkk1 to the
exogenously applied Dkk1 in our experiments, we relied on an
experiment in which 10
5 MCF-7 cells were seeded in volume of
200 ml for 24 hours. The medium contained 38432 pg/ml Dkk,
measured by ELISA [32]. To calculate the total volume of the
medium into which Dkk1 was secreted in our simulations the
representative medium volume of 2?10
23 ml/cell was multiplied by
the number of cells in each simulation at steady state. Using
average results from 50 simulations, we derived the model–specific
Dkk1 unit as 2.01 ng/mL.
Cell lines
MCF-7 cells (American Type Culture Collection, Manassas,
VA) were maintained in DMEM with 10% fetal calf serum,
100 U/mL penicillin, 100 mg/mL streptomycin, and 29.2 mg/mL
L-glutamine (all from Gibco, Carlsbad, CA). Cells were passaged
when reached 90 percent confluency by trypsinization and
reseeding at 20 percent of initial density.
Primary invasive human BC cells
Pleural effusion samples were collected with informed consent
(COREC #05/Q1402/25) from 3 patients suffering from
estrogen receptor-positive (ER+) metastatic BC. Cells were
collected by centrifugation at 800 6g for 5 minutes and
resuspended in PBS. Blood cells were removed by centrifugation
of the cell suspension through Lymphoprep solution (Axis Shield;
Norton, MA) at 800 6g for 20 minutes. Then the remaining
leukocytes cells were removed by CD45–specific immunomagnetic
adsorption; first, the cells were resuspended at #1610
6 in 100 mL
PBS containing 0.5 percent BSA, 2.0 mM EDTA (sorting buffer)
and incubated with immunomagnetic reagent specific for human
CD45 (1:10, Miltenyi Biotec, Auburn, CA) for 15 minutes at 40uC.
Cells were then washed and resuspended in 500 mL of sorting
buffer, passed through the magnetic column of an AutoMACS
apparatus running under the normal of DEPLETES program and
the CD45–negative cells were collected. Finally, the cells were
incubated with 100 mL of Dead Cell Removal microbeads and the
dead cells were removed using an MS column on a MACS
seperator (all from Miltenyi Biotec). Live cells were collected,
resuspended in the MS medium (DMEM:F12) supplemented with
B27 and MEGM SingleQuots (human epidermal growth factor,
insulin, hydrocortisone, and GA-1000; Gibco). All procedures
involving human samples were approved by the Local Research
Ethics Committee.
Mammosphere forming assay
A single cell suspension was prepared from MCF-7 monolayer
culture using enzymatic digestion (Trypsin–EDTA, Gibco) and
mechanical disaggregation by repeated passing through a gauge
25 needle. The cells were plated at a density of 500 cells/cm
2 in
culture flasks coated with 2-hydroxyethylmethacrylate; poly-
HEMA (Sigma) to prevent cell anchorage. Cells were grown for
seven days in the MS medium in a humidified atmosphere of 5%
CO2 at 37uC. Spheres over 50 mM were counted. Assuming that
each MS was the clonal product of a single BC–SC, we divided the
number of MSs with the total numbers of cells plated and derived
the MS forming cell fraction (MF). Primary breast cancer cell MS
were prepared and counted in a similar way.
Flow cytometry of CD44
+CD24
-/low cells
Trypsinized MCF-7 cells were resuspended at #1610
6 cells/
100 mL PBS containing 2.0 mM EDTA and 0.5 percent BSA
(‘‘buffer’’) and incubated with fluorescein–conjugated antibodies
specific for CD44 and phycoerythrin–conjugated antibody specific
for CD24 (both at 1:10 dilution, Beckman Coulter, High
Wycombe, UK) at 40uC for 10 min. Following incubation, the
cells were washed in PBS and centrifuged at 8006g for two
minutes. Cells were resuspended in 500 mL of the buffer and
fluorescence was measured using a FACSCalibur flow cytometer
(Becton Dickinson, Oxford, UK). The data were analyzed with the
aid of WinMDI 2.8 software (Scripps Institute, San Diego, CA).
NOTCH pathway activation and inhibition
To quantify Delta4 activation, 100 mg/mL rhDLL4 (R&D
Systems, Abingdon, UK) was dissolved in PBS containing 0.1
percent BSA and stored at 220uC. One day before use, the stock
solution of rhDLL4 was diluted 1:100 in PBS containing 0.2
percent gelatine (Sigma) and used to coat T75 flasks (Gibco,
Carlsbad, CA). The flasks were then incubated at 40uC overnight.
The next day, the solution was removed and 3610
6 MCF-7 cells
were plated, grown for 24 to 48 h, then taken for MS forming
assay and flow cytometry of CD44
+CD24
-/low cells.
To determine the effects of c-secretase on SC proliferation, c-
secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl-l-alanyl)]-
S-phenylglycine t-butyl ester; Calbiochem, Nottingham, UK) was
added at 10 mM to adherent cells or MSs at the day of plating.
Controls were treated with 0.001 percent DMSO (Sigma).
siRNAs designed to interfere with four unique sites in the
Notch4 receptor were used from the ON_TARGETplus set
(Dharmacon, Lafayette CO; siRNA ID and sequence: J-011883-
05–GCACGGACGGUGUCAGUAA, J-011883-06–GCAGGA-
GGGUCCA CGUUGU, J-011883-07–GGUGAGACGUGCCA-
GUUUC, J-011883-08–GCCCAACCCUGC GAUAAU-G). One
million MCF-7 cells were plated 24 h before transfection with
siRNA primers. Briefly, sequence-specific siRNA primers and a
scrambled sequence Control were diluted to 20 mM. Dharmafect4
transfection reagent was made up in Optimem serum–free
medium and added to cells for 72 h as recommended by the
manufacturer.
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One million MCF-7 cells were cultured in T75 flasks for 48 h
when they were washed with PBS. Then the cells were incubated
in serum–free medium [phenol-red–free DMEM (Gibco) with
penicillin/streptomycin and L-glutamine] for 24 h. Cells were
further treated with Dkk1 at 1, 5, 10, 50 or 100 ng/mL for 24 h or
48 h and trypsinized (0.125 percent Trypsin-EDTA; Worthington
Biochemical Corporation, Lakewood, NJ) immediately thereafter.
To maintain Dkk1 concentration in culture, the medium was
refreshed daily. Collected cells were taken for MS forming assay
and flow cytometry of CD44
+CD24
-/low cells. In the MS forming
assay cells were plated in the MS medium for seven days (i) in the
absence of Dkk, (ii) with a single addition of Dkk1 or (iii) with
medium refreshment Dkk1 every 24 h.
Statistical Analysis
Normally distributed data were analyzed by the analysis of
variance to determine significant differences of Dkk1 treatment
followed by individual comparisons to Control (no Dkk1) using a
two-sided t-test. Data not distributed normally were analyzed by
the Kruskall-Wallis test followed by individual comparisons to
normal using the Mann–Whitney U test. P values equal to and less
than 0.05 were taken to indicate statistically significant differences.
Supporting Information
Text S1 The assumptions underlying all the model
equations and their biological justification, as well as
all the model equations and their derivation.
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